138P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC): RATIONALE-304 updated analysis

S. Lu,J. Wang,Y. Yu,X. Yu,Y. Hu,Z. Ma,X. Li,W. He,Y. Bao,M. Wang
DOI: https://doi.org/10.1016/j.iotech.2022.100250
2022-01-01
Immuno-Oncology and Technology
Abstract:Interim analysis of the open-label phase 3 RATIONALE-304 study (NCT03663205) demonstrated clinical benefit of tislelizumab (TIS) plus chemotherapy (chemo) as first-line (1L) therapy in patients with advanced nsq-NSCLC vs chemo alone, with significantly improved progression-free survival (PFS) and a manageable safety profile. Here, we report the updated results.
What problem does this paper attempt to address?